Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Molecular Profiling of Docetaxel-Resistant Prostate Cancer Cells Identifies Multiple Mechanisms of Therapeutic Resistance

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. The Urokinase Receptor (uPAR) as a "Trojan Horse" in Targeted Cancer Therapy: Challenges and Opportunities

    Research output: Contribution to journalReviewResearchpeer-review

  2. Nationwide Survival Benefit after Implementation of First-Line Immunotherapy for Patients with Advanced NSCLC-Real World Efficacy

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Meningioma-Brain Crosstalk: A Scoping Review

    Research output: Contribution to journalReviewResearchpeer-review

  4. Pathologic Characteristics of Pregnancy-Related Meningiomas

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Basal Cell Carcinoma of Prostate With MSMB-NCOA4 Fusion and a Probable Basal Cell Carcinoma In Situ: Case Report

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Risk of depression after diagnostic prostate cancer workup - A nationwide, registry-based study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Detection of Clinically Significant Prostate Cancer by Systematic TRUS-Biopsies in a Population-Based Setting Over a 20 Year Period

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Antidepressant prescriptions and associated factors in men with prostate cancer and their female partners

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Docetaxel-a taxane-based chemotherapeutic agent-was the first treatment to demonstrate significant improvements in overall survival in men with metastatic castration-resistant prostate cancer (mCRPC). However, the response to docetaxel is generally short-lived, and relapse eventually occurs due to the development of resistance. To explore the mechanisms of acquired docetaxel resistance in prostate cancer (PCa) and set these in the context of androgen deprivation therapy, we established docetaxel-resistant PCa cell lines, derived from the androgen-dependent LNCaP cell line, and from the LNCaP lineage-derived androgen-independent C4-2B sub-line. We generated two docetaxel-resistant LNCaPR and C4-2BR sub-lines, with IC50 values 77- and 50-fold higher than those of the LNCaP and C4-2B parental cells, respectively. We performed gene expression analysis of the matched sub-lines and found several alterations that may confer docetaxel resistance. In addition to increased expression of ABCB1, an ATP-binding cassette (ABC) transporter, and a well-known gene associated with development of docetaxel resistance, we identified genes associated with androgen signaling, cell survival, and overexpression of ncRNAs. In conclusion, we identified multiple mechanisms that may be associated with the development of taxane drug resistance in PCa. Actioning these mechanisms could provide a potential approach to re-sensitization of docetaxel-resistant PCa cells to docetaxel treatment and thereby further add to the life-prolonging effects of this drug in men with mCRPC.

Original languageEnglish
Article number1290
JournalCancers
Volume13
Issue number6
Pages (from-to)1-20
Number of pages20
ISSN2072-6694
DOIs
Publication statusPublished - 14 Mar 2021

    Research areas

  • Androgen independence, Cellular models, Docetaxel resistance, Prostate cancer

ID: 67023945